Allurion launches pivotal US Elipse gastric balloon trial

February 6, 2018 By Fink Densford Leave a Comment

Allurion Technologies said today it launched the pivotal Enlighten US clinical trial of its Elipse gastric balloon designed for weight loss.

The Elipse gastric balloon is made of a thin, flexible polymer film and is ingested as a capsule without the need for surgery. The balloon is filled once it reaches a patient’s stomach to reduce hunger, and passes naturally through the GI tract after 4 months, the Natick, Mass.-based company said.

“The start of the Enlighten clinical trial is not only a milestone for the Elipse Balloon, but also for the field of weight loss more broadly. Non-surgical weight loss therapies will help treat those who have not seen success from dieting alone. Having now treated the first patients in Enlighten, we are one step closer to having a next-generation tool to offer those in need of a solution,” principal investigator Dr. Jaime Ponce of the Chattanooga Memorial Hospital Weight Management Center said in a prepared statement.

The 400-patient Enlighten study looks to explore the safety and efficacy of the Elipse balloon across 12 US centers, Allurion Technologies said.

“We are looking forward to adding to our global clinical trial experience with the Elipse Balloon. Starting Enlighten is the first step toward bringing our flagship product to the United States where we can build upon the success we have had abroad,” chief medical officer Dr. Ram Chuttani said in a press release.

“The Elipse Balloon has the potential to revolutionize the way obesity is treated in the United States. Millions of Americans are struggling to lose weight, and they are calling for new options that are safe and effective. The Enlighten study is the next step in meeting this consumer need,” CEO Dr. Shantanu Gaur said in prepared remarks.

Last July, Allurion said it raised $27 million in a Series C round of funding to support its Elipse gastric balloon designed for weight loss.

New 510(k) boosts iRhythm, Verily efforts for AFib screening
The latest 510(k) clearance for the Verily Study Watch will further the efforts of the Google sister company and iRhythm Technologies (NSDQ:IRTC) to improve atrial fibrillation treatment. Verily — a life science company under Alphabet (NSDQ:GOOGL) — recently received an FDA 510(k) clearance to include an irregular pulse monitor in its Study Watch wearable. “We’ve worked carefully to meet the FDA’s stringent… […]
Argon Medical debuts IVC filter retrieval kits
Argon Medical Devices (Frisco, Texas) said this week that it has launched single-loop and triple-loop retrieval kits for percutaneous removal of inferior vena cava (IVC) filters that are no longer medically required. The kits are indicated for use via a jugular approach and offer the following features: A coil-reinforced outer sheath with the strength needed… […]
NANS 2020: Neuromodulation news you need to know
Neuromodulation devices from companies including Medtronic (NYSE:MDT), Abbott (NYSE:ABT) and SPR Therapeutics are showing promise treating pain. That’s one of the initial takeaways from study results that medical device companies in the neuromodulation space are touting this weekend at NANS 2020 in Las Vegas. NANS is a joint conference of Congress of Neurological Surgeons and the North American Neuromodulation… […]
Injection Molding Principles
Optimizing custom part designs for injection molding requires a thorough understanding of the process and outcomes. In this e-book, you’ll learn about common molding resins, special molding terms you should know, and most importantly, how to optimize your part with undercuts, even walls, drafts, and more. Download this e-book from Xometry to learn more… The […]
GW Plastics expands Vermont manufacturing and tech center
GW Plastics announced that it has completed a $10 million expansion of its Royalton, Vt., manufacturing and technology center. The company said it has added a 30,000 ft2 to the building to accommodate the growth of its thermoplastic injection molding and medical device contract assembly business. The expansion includes a new 13,000 ft2, Class 8… […]
Certain GE Healthcare patient-monitoring devices vulnerable to cyberattack
The federal government and GE Healthcare (NYSE:GE) announced today that the certain of the company’s patient monitoring devices are vulnerable to cyberattack. If attacked, some versions of the Carescape and ApexPro telemetry servers, the Carescape Central Station version 1 and Central Information Center systems could stop monitoring patients, silence alarms or produce unnecessary alarms during… […]
Cardinal Health recalls 9 million surgical gowns, sends hospitals scrambling
Cardinal Health (NYSE:CAH) announced that it is voluntarily recalling 9.1 million surgical gowns produced by an unnamed contract manufacturer after discovering quality issues with the product. The Dublin, Ohio-based company said that some gowns were produced in unapproved locations that did not maintain proper environmental conditions as required by law. Some of the gowns were also… […]
KNF launches compact swing piston pump
KNF Neuberger is touting its NPK 06 swing piston micro gas pumps, designed to deliver high-flow and high-pressure performance in a compact size. The new pumps work well for medical diagnostics, therapy, monitoring, and general compression applications, according to the Trenton, N.J.-based company. NPK 06 measures 1.85” (47mm) wide and can produce free flow up… […]
Heraeus Medical Components and Myant partner on electrical sensing for textiles
Heraeus Medical Components (St. Paul, Minn.) and Toronto-based Myant have entered a partnership enabling Myant to use Heraeus’ Tectitoat for electrical sensing applications in textiles, the companies announced today. Tecticoat is a conductive polymer-based coating that can be applied to textiles to control electrical conductivity, electromagnetic shielding and electrostatic dissipation, making it suitable for integration… […]
Cook Medical’s peripheral artery set debuts in U.S.
Cook Medical recently announced the U.S. launch of its TriForce peripheral crossing set to support vascular obstruction procedures. The TriForce set is designed to be percutaneously introduced into blood vessels to support a wire guide while performing a peripheral intervention, according to the Bloomington, Ind.-based company. This device is also intended for injection of radiopaque… […]
Bayer and Exscientia partner to bring AI to drug discovery
Bayer (ETR:BAYN) announced that it is entering into a collaboration agreement with artificial intelligence drug discovery company Exscientia to identify and optimize novel lead structures for potential drug candidates in treating cardiovascular and oncological diseases. The agreement, announced earlier this month, is slated to see the companies work together on early research projects combining Exscientia’s proprietary… […]